Therapy Pathways in the Treatment of Hormone Naive Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormon-Releasing-Hormon (LHRH) Agonists. (ProComD)
Phase of Trial: Phase IV
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs Degarelix (Primary) ; Buserelin; Goserelin; Leuprorelin; Triptorelin
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms ProComD
- Sponsors Ferring Pharmaceuticals
- 01 Jul 2019 Status changed from active, no longer recruiting to completed.
- 10 Jan 2019 Planned End Date changed from 1 Dec 2020 to 1 Jun 2019.
- 10 Jan 2019 Planned primary completion date changed from 1 Dec 2020 to 1 Jun 2019.